{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T11:02:07Z","timestamp":1785927727765,"version":"3.56.0"},"reference-count":63,"publisher":"Bentham Science Publishers Ltd.","issue":"12","funder":[{"DOI":"10.13039\/100007688","name":"American University of Beirut","doi-asserted-by":"publisher","award":["320133"],"award-info":[{"award-number":["320133"]}],"id":[{"id":"10.13039\/100007688","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Raynaud&amp;#039;s Phenomenon (RP) results from exaggerated cold-induced vasoconstriction. RP\npatients suffer from vasospastic attacks and compromised digital blood perfusion leading to a triple\ncolor change at the level the fingers. Severe RP may cause ulcers and threaten tissue viability. Many\ndrugs have been used to alleviate the symptoms of RP. These include calcium-channel blockers,\ncGMP-specific phosphodiesterase type 5 inhibitors, prostacyclin analogs, and angiotensin receptor\nblockers. Despite their variety, these drugs do not treat RP but rather alleviate its symptoms. To\ndate, no drug for RP has been yet approved by the U.S Food and Drugs Administration. Cilostazol is\na selective inhibitor of phosphodiesterase-III, originally prescribed to treat intermittent claudication.\nOwing to its antiplatelet and vasodilating properties, cilostazol is being repurposed as a potential\ndrug for RP. This review focuses on the different lines of action of cilostazol serving to enhance\nblood perfusion in RP patients.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200903114154","type":"journal-article","created":{"date-parts":[[2020,9,3]],"date-time":"2020-09-03T16:54:47Z","timestamp":1599152087000},"page":"2409-2417","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Repurposing Cilostazol for Raynaud's Phenomenon"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5778-5342","authenticated-orcid":true,"given":"Nehme","family":"El-Hachem","sequence":"first","affiliation":[{"name":"Laboratory of Medical Genetics, Institute of Experimental Cardiology, National Medical Research Center of Cardiology, Beirut,Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1421-124X","authenticated-orcid":true,"given":"Manal M.","family":"Fardoun","sequence":"additional","affiliation":[{"name":"Department of Biology, American University of Beirut, Beirut,Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4597-3642","authenticated-orcid":true,"given":"Hasan","family":"Slika","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut,Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5632-1175","authenticated-orcid":true,"given":"Elias","family":"Baydoun","sequence":"additional","affiliation":[{"name":"Department of Biology, American University of Beirut, Beirut,Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3004-5675","authenticated-orcid":true,"given":"Ali H.","family":"Eid","sequence":"additional","affiliation":[{"name":"Department of Pharmacology and Toxicology, Faculty of Medicine, American University of Beirut, Beirut,Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"573","volume":"51","author":"Vane J.R.","year":"2000","unstructured":"Vane J.R.; The fight against rheumatism: from willow bark to COX-1 sparing drugs. J Physiol Pharmacol 2000,51(4 Pt 1),573-586","journal-title":"J Physiol Pharmacol"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1111\/bjh.14520","volume":"177","author":"Desborough M.J.R.","year":"2017","unstructured":"Desborough M.J.R.; Keeling D.M.; The aspirin story - from willow to wonder drug. Br J Haematol 2017,177(5),674-683","journal-title":"Br J Haematol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrd3781","volume":"11","author":"Flemming A.","year":"2012","unstructured":"Flemming A.; Cancer: Of targets and anti-targets. Nat Rev Drug Discov 2012,11(7),515","journal-title":"Nat Rev Drug Discov"},{"key":"ref=4","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.13273","author":"Jourdan J.P.","year":"2020","unstructured":"Jourdan J.P.; Bureau R.; Rochais C.; Dallemagne P.; Drug repositioning: a brief overview. J Pharm Pharmacol 2020","journal-title":"J Pharm Pharmacol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s40265-017-0689-1","volume":"77","author":"Holstein S.A.","year":"2017","unstructured":"Holstein S.A.; McCarthy P.L.; Immunomodulatory drugs in multiple myeloma: mechanisms of action and clinical experience. Drugs 2017,77(5),505-520","journal-title":"Drugs"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.semcancer.2020.03.005","volume":"68","author":"Kale V.P.","year":"2020","unstructured":"Kale V.P.; Habib H.; Chitren R.; Patel M.; Pramanik K.C.; Jonnalagadda S.C.; Challagundla K.; Pandey M.K.; Old drugs, new uses: drug repurposing in hematological malignancies. Semin Cancer Biol 2020,68,242-248","journal-title":"Semin Cancer Biol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.sxmr.2018.06.005","volume":"7","author":"Goldstein I.","year":"2019","unstructured":"Goldstein I.; Burnett A.L.; Rosen R.C.; Park P.W.; Stecher V.J.; The serendipitous story of sildenafil: an unexpected oral therapy for erectile dysfunction. Sex Med Rev 2019,7(1),115-128","journal-title":"Sex Med Rev"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1161\/CIRCRESAHA.107.162511","volume":"101","author":"Kass D.A.","year":"2007","unstructured":"Kass D.A.; Champion H.C.; Beavo J.A.; Phosphodiesterase type 5: expanding roles in cardiovascular regulation. Circ Res 2007,101(11),1084-1095","journal-title":"Circ Res"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"113894","DOI":"10.1016\/j.bcp.2020.113894","volume":"177","author":"Gelosa P.","year":"2020","unstructured":"Gelosa P.; Castiglioni L.; Camera M.; Sironi L.; Drug repurposing in cardiovascular diseases: Opportunity or hopeless dream? Biochem Pharmacol 2020,177,113894","journal-title":"Biochem Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","DOI":"10.4324\/9781315373669","volume":"Vol. 1","author":"Dudley J.","year":"2017","unstructured":"Dudley J.; Berliocchi L.;  Drug repositioning: approaches and applications for neurotherapeutics 2017,Vol. 1","journal-title":"Drug repositioning: approaches and applications for neurotherapeutics"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.1016\/j.jvs.2013.03.012","volume":"57","author":"Landry G.J.","year":"2013","unstructured":"Landry G.J.; Current medical and surgical management of Raynaud\u2019s syndrome. J Vasc Surg 2013,57(6),1710-1716","journal-title":"J Vasc Surg"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrrheum.2012.96","volume":"8","author":"Herrick A.L.","year":"2012","unstructured":"Herrick A.L.; The pathogenesis, diagnosis and treatment of Raynaud phenomenon. Nat Rev Rheumatol 2012,8(8),469-479","journal-title":"Nat Rev Rheumatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1007\/s10067-019-04745-5","volume":"38","author":"Pauling J.D.","year":"2019","unstructured":"Pauling J.D.; Hughes M.; Pope J.E.; Raynaud\u2019s phenomenon-an update on diagnosis, classification and management. Clin Rheumatol 2019,38(12),3317-3330","journal-title":"Clin Rheumatol"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1016\/S0140-6736(00)05118-7","volume":"357","author":"Block J.A.","year":"2001","unstructured":"Block J.A.; Sequeira W.; Raynaud\u2019s phenomenon. Lancet 2001,357(9273),2042-2048","journal-title":"Lancet"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.autrev.2013.12.001","volume":"13","author":"Prete M.","year":"2014","unstructured":"Prete M.; Fatone M.C.; Favoino E.; Perosa F.; Raynaud\u2019s phenomenon: from molecular pathogenesis to therapy. Autoimmun Rev 2014,13(6),655-667","journal-title":"Autoimmun Rev"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3389\/fphar.2016.00438","volume":"7","author":"Fardoun M.M.","year":"2016","unstructured":"Fardoun M.M.; Nassif J.; Issa K.; Baydoun E.; Eid A.H.; Raynaud\u2019s phenomenon: a brief review of the underlying mechanisms. Front Pharmacol 2016,7,438","journal-title":"Front Pharmacol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"798","DOI":"10.20452\/pamw.15008","volume":"129","author":"Lis-\u015awi\u0119ty A.","year":"2019","unstructured":"Lis-\u015awi\u0119ty A.; Recent advances in the workup and management of Raynaud phenomenon Pol. Arch Intern Med 2019,129(11),798-808","journal-title":"Arch Intern Med"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1016\/j.jaad.2008.06.004","volume":"59","author":"Bakst R.","year":"2008","unstructured":"Bakst R.; Merola J.F.; Franks A.G.; Sanchez M.; Raynaud\u2019s phenomenon: pathogenesis and management. J Am Acad Dermatol 2008,59(4),633-653","journal-title":"J Am Acad Dermatol"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"401","DOI":"10.4314\/ejhs.v26i4.13","volume":"26","author":"Sama C-B.","year":"2016","unstructured":"Sama C-B.; Post-traumatic dgital gangrene associated with epinephrine use in primary Raynaud\u2019s phenomenon: lesson for the future. Ethiop J Health Sci 2016,26(4),401-404","journal-title":"Ethiop J Health Sci"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1152\/japplphysiol.00298.2010","volume":"109","author":"Charkoudian N.","year":"2010","unstructured":"Charkoudian N.; Mechanisms and modifiers of reflex induced cutaneous vasodilation and vasoconstriction in humans. J Appl Physiol 2010,109(4),1221-1228","journal-title":"J Appl Physiol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1056\/NEJMra1507638","volume":"375","author":"Wigley F.M.","year":"2016","unstructured":"Wigley F.M.; Flavahan N.A.; Raynaud\u2019s Phenomenon. N Engl J Med 2016,375(6),556-565","journal-title":"N Engl J Med"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"H1075","DOI":"10.1152\/ajpheart.2000.278.4.H1075","volume":"278","author":"Chotani M.A.","year":"2000","unstructured":"Chotani M.A.; Flavahan S.; Mitra S.; Daunt D.; Flavahan N.A.; Silent alpha(2C)-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000,278(4),H1075-H1083","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0165-6147(97)01063-8","volume":"18","author":"MacDonald E.","year":"1997","unstructured":"MacDonald E.; Kobilka B.K.; Scheinin M.; Gene targeting--homing in on \u03b1 2-adrenoceptor-subtype function. Trends Pharmacol Sci 1997,18(6),211-219","journal-title":"Trends Pharmacol Sci"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"18448","DOI":"10.1016\/S0021-9258(17)32329-3","volume":"269","author":"von Zastrow M.","year":"1994","unstructured":"von Zastrow M.; Kobilka B.K.; Antagonist-dependent and -independent steps in the mechanism of adrenergic receptor internalization. J Biol Chem 1994,269(28),18448-18452","journal-title":"J Biol Chem"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"1367","DOI":"10.1161\/01.RES.0000128407.45014.58","volume":"94","author":"Bailey S.R.","year":"2004","unstructured":"Bailey S.R.; Eid A.H.; Mitra S.; Flavahan S.; Flavahan N.A.; Rho kinase mediates cold-induced constriction of cutaneous arteries: role of \u03b12C-adrenoceptor translocation. Circ Res 2004,94(10),1367-1374","journal-title":"Circ Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1124\/mol.60.6.1195","volume":"60","author":"Jeyaraj S.C.","year":"2001","unstructured":"Jeyaraj S.C.; Chotani M.A.; Mitra S.; Gregg H.E.; Flavahan N.A.; Morrison K.J.; Cooling evokes redistribution of \u03b12C-adrenoceptors from golgi to plasma membrane in transfected human embryonic kidney 293 cells. Mol Pharmacol 2001,60(6),1195-1200","journal-title":"Mol Pharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"C499","DOI":"10.1152\/ajpcell.00461.2011","volume":"303","author":"Jeyaraj S.C.","year":"2012","unstructured":"Jeyaraj S.C.; Unger N.T.; Eid A.H.; Mitra S.; Paul El-Dahdah N.; Quilliam L.A.; Flavahan N.A.; Chotani M.A.; Cyclic AMP-Rap1A signaling activates RhoA to induce \u03b1(2c)-adrenoceptor translocation to the cell surface of microvascular smooth muscle cells. Am J Physiol Cell Physiol 2012,303(5),C499-C511","journal-title":"Am J Physiol Cell Physiol"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"H266","DOI":"10.1152\/ajpheart.00084.2008","volume":"295","author":"Eid A.H.","year":"2008","unstructured":"Eid A.H.; Chotani M.A.; Mitra S.; Miller T.J.; Flavahan N.A.; Cyclic AMP acts through Rap1 and JNK signaling to increase expression of cutaneous smooth muscle alpha(2C)-adrenoceptors. Am J Physiol Heart Circ Physiol 2008,295(1),H266-H272","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=29","first-page":"83","volume":"11","author":"Halawa B.","year":"2001","unstructured":"Halawa B.; Calcium channel blockers in the treatment of cardiovascular disease. Pol Merkur Lekarski 2001,11(61),83-87","journal-title":"Pol Merkur Lekarski"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1097\/00002281-199811000-00013","volume":"10","author":"Sturgill M.G.","year":"1998","unstructured":"Sturgill M.G.; Seibold J.R.; Rational use of calcium-channel antagonists in Raynaud\u2019s phenomenon. Curr Opin Rheumatol 1998,10(6),584-588","journal-title":"Curr Opin Rheumatol"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000467.pub2","author":"Rirash F.","year":"2017","unstructured":"Rirash F.; Tingey P.C.; Harding S.E.; Maxwell L.J.; Tanjong Ghogomu E.; Wells G.A.; Tugwell P.; Pope J.; Calcium channel blockers for primary and secondary Raynaud\u2019s phenomenon. Cochrane Database Syst Rev 12CD000467.2017","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=32","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002069.pub5","author":"Ennis H.","year":"2016","unstructured":"Ennis H.; Hughes M.; Anderson M.E.; Wilkinson J.; Herrick A.L.; Calcium channel blockers for primary Raynaud\u2019s phenomenon. Cochrane Database Syst Rev 2CD002069.2016","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s10238-019-00553-y","volume":"19","author":"Negrini S.","year":"2019","unstructured":"Negrini S.; Magnani O.; Matucci-Cerinic M.; Carignola R.; Data V.; Montabone E.; Santaniello A.; Adorni G.; Murdaca G.; Puppo F.; Indiveri F.; Della Rossa A.; D\u2019Ascanio A.; Barsotti S.; Giuggioli D.; Ferri C.; Lumetti F.; Bosello S.L.; Canestrari G.; Bellando Randone S.; Bruni C.; Guiducci S.; Battaglia E.; De Andres M.I.; Russo A.A.; Beretta L.; Iloprost use and medical management of systemic sclerosis-related vasculopathy in Italian tertiary referral centers: results from the PROSIT study. Clin Exp Med 2019,19(3),357-366","journal-title":"Clin Exp Med"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1093\/rheumatology\/ket417","volume":"53","author":"Lee E.Y.","year":"2014","unstructured":"Lee E.Y.; Park J.K.; Lee W.; Kim Y.K.; Park C.S.; Giles J.T.; Park J.W.; Shin K.; Lee J.S.; Song Y.W.; Lee E.B.; Head-to-head comparison of udenafil vs amlodipine in the treatment of secondary Raynaud\u2019s phenomenon: a double-blind, randomized, cross-over study. Rheumatology (Oxford) 2014,53(4),658-664","journal-title":"Rheumatology (Oxford)"},{"key":"ref=35","first-page":"123","volume":"113","author":"Temprano K.K.","year":"2016","unstructured":"Temprano K.K.; A review of raynaud\u2019s disease. Mo Med 2016,113(2),123-126","journal-title":"Mo Med"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.2174\/1381612820666141112160013","volume":"21","author":"Regulski M.","year":"2015","unstructured":"Regulski M.; Regulska K.; Stanisz B.J.; Murias M.; Gieremek P.; Wzgarda A.; Niznik B.; Chemistry and pharmacology of angiotensin-converting enzyme inhibitors. Curr Pharm Des 2015,21(13),1764-1775","journal-title":"Curr Pharm Des"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1024\/0301-1526\/a000526","volume":"45","author":"Linnemann B.","year":"2016","unstructured":"Linnemann B.; Erbe M.; Raynaud\u2019s phenomenon and digital ischaemia--pharmacologic approach and alternative treatment options. Vasa 2016,45(3),201-212","journal-title":"Vasa"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2165\/00002018-200326120-00004","volume":"26","author":"Agust\u00ed A.","year":"2003","unstructured":"Agust\u00ed A.; Bonet S.; Arnau J.M.; Vidal X.; Laporte J.R.; Adverse effects of ACE inhibitors in patients with chronic heart failure and\/or ventricular dysfunction: meta-analysis of randomised clinical trials. Drug Saf 2003,26(12),895-908","journal-title":"Drug Saf"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1056\/NEJMcp013013","volume":"347","author":"Wigley F.M.","year":"2002","unstructured":"Wigley F.M.; Clinical practice. Raynaud\u2019s phenomenon. N Engl J Med 2002,347(13),1001-1008","journal-title":"N Engl J Med"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.2174\/157489009787260025","volume":"4","author":"Dindyal S.","year":"2009","unstructured":"Dindyal S.; Kyriakides C.; A review of cilostazol, a phosphodiesterase inhibitor, and its role in preventing both coronary and peripheral arterial restenosis following endovascular therapy. Recent Pat Cardiovasc Drug Discov 2009,4(1),6-14","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"ref=41","unstructured":"Orange book: approved drug products with therapeutic\nequivalence evaluations. Available at: (acceesed on: 24 March, 2021)"},{"key":"ref=42","first-page":"11","author":"Cariski A.T.","year":"2001","unstructured":"Cariski A.T.; Cilostazol: a novel treatment option in intermittent claudication. Int J Clin Pract Suppl 2001(119),11-18","journal-title":"Int J Clin Pract Suppl"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"CD003748","DOI":"10.1002\/14651858.cd003748.pub4","volume":"2014","author":"Bedenis R.","year":"2014","unstructured":"Bedenis R.; Stewart M.; Cleanthis M.; Robless P.; Mikhailidis D.P.; Stansby G.; Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014,2014(10),CD003748","journal-title":"Cochrane Database Syst Rev"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1123\/jab.28.2.184","volume":"28","author":"Yentes J.M.","year":"2012","unstructured":"Yentes J.M.; Huisinga J.M.; Myers S.A.; Pipinos I.I.; Johanning J.M.; Stergiou N.; Pharmacological treatment of intermittent claudication does not have a significant effect on gait impairments during claudication pain. J Appl Biomech 2012,28(2),184-191","journal-title":"J Appl Biomech"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1474-4422(10)70198-8","volume":"9","author":"Shinohara Y.","year":"2010","unstructured":"Shinohara Y.; Katayama Y.; Uchiyama S.; Yamaguchi T.; Handa S.; Matsuoka K.; Ohashi Y.; Tanahashi N.; Yamamoto H.; Genka C.; Kitagawa Y.; Kusuoka H.; Nishimaru K.; Tsushima M.; Koretsune Y.; Sawada T.; Hamada C.; CSPS 2 group. Cilostazol for prevention of secondary stroke (CSPS 2): an aspirin-controlled, double-blind, randomised non-inferiority trial. Lancet Neurol 2010,9(10),959-968","journal-title":"Lancet Neurol"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1161\/STROKEAHA.119.026655","volume":"50","author":"Kim S.M.","year":"2019","unstructured":"Kim S.M.; Jung J.M.; Kim B.J.; Lee J.S.; Kwon S.U.; Cilostazol mono and combination treatments in ischemic stroke: an updated systematic review and meta-analysis. Stroke 2019,50(12),3503-3511","journal-title":"Stroke"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1161\/01.STR.0000157667.06542.b7","volume":"36","author":"Kwon S.U.","year":"2005","unstructured":"Kwon S.U.; Cho Y.J.; Koo J.S.; Bae H.J.; Lee Y.S.; Hong K.S.; Lee J.H.; Kim J.S.; Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke 2005,36(4),782-786","journal-title":"Stroke"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1053\/j.jvca.2014.06.028","volume":"29","author":"Nazli Y.","year":"2015","unstructured":"Nazli Y.; Colak N.; Namuslu M.; Erdamar H.; Haltas H.; Alpay M.F.; Nuri Aksoy O.; Olgun Akkaya I.; Cakir O.; Cilostazol attenuates spinal cord ischemia-reperfusion injury in rabbits. J Cardiothorac Vasc Anesth 2015,29(2),351-359","journal-title":"J Cardiothorac Vasc Anesth"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1016\/S0024-3205(01)01258-9","volume":"69","author":"Nakamura T.","year":"2001","unstructured":"Nakamura T.; Houchi H.; Minami A.; Sakamoto S.; Tsuchiya K.; Niwa Y.; Minakuchi K.; Nakaya Y.; Endothelium-dependent relaxation by cilostazol, a phosphodiesteras III inhibitor, on rat thoracic aorta. Life Sci 2001,69(15),1709-1715","journal-title":"Life Sci"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.vph.2015.01.002","volume":"70","author":"Li H.","year":"2015","unstructured":"Li H.; Hong D.H.; Son Y.K.; Na S.H.; Jung W.K.; Bae Y.M.; Seo E.Y.; Kim S.J.; Choi I.W.; Park W.S.; Cilostazol induces vasodilation through the activation of Ca(2+)-activated K(+) channels in aortic smooth muscle. Vascul Pharmacol 2015,70,15-22","journal-title":"Vascul Pharmacol"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/j.1527-3466.2001.tb00076.x","volume":"19","author":"Liu Y.","year":"2001","unstructured":"Liu Y.; Shakur Y.; Yoshitake M.; Kambayashi Ji J.; Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001,19(4),369-386","journal-title":"Cardiovasc Drug Rev"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1097\/00005344-200009000-00011","volume":"36","author":"Liu Y.","year":"2000","unstructured":"Liu Y.; Fong M.; Cone J.; Wang S.; Yoshitake M.; Kambayashi J.; Inhibition of adenosine uptake and augmentation of ischemia-induced increase of interstitial adenosine by cilostazol, an agent to treat intermittent claudication. J Cardiovasc Pharmacol 2000,36(3),351-360","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/S0002-9149(97)00256-7","volume":"79","author":"Shryock J.C.","year":"1997","unstructured":"Shryock J.C.; Belardinelli L.; Adenosine and adenosine receptors in the cardiovascular system: biochemistry, physiology, and pharmacology. Am J Cardiol 1997,79(12A),2-10","journal-title":"Am J Cardiol"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"97","DOI":"10.3109\/03009749309099251","volume":"22","author":"Lau C.S.","year":"1993","unstructured":"Lau C.S.; McLaren M.; Saniabadi A.; Belch J.J.; Increased whole blood platelet aggregation in patients with Raynaud\u2019s phenomenon with or without systemic sclerosis. Scand J Rheumatol 1993,22(3),97-101","journal-title":"Scand J Rheumatol"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1055\/s-0037-1615217","volume":"80","author":"Nomura S.","year":"1998","unstructured":"Nomura S.; Shouzu A.; Omoto S.; Hayakawa T.; Kagawa H.; Nishikawa M.; Inada M.; Fujimura Y.; Ikeda Y.; Fukuhara S.; Effect of cilostazol on soluble adhesion molecules and platelet-derived microparticles in patients with diabetes. Thromb Haemost 1998,80(3),388-392","journal-title":"Thromb Haemost"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"56B","DOI":"10.1016\/S0828-282X(06)70987-4","volume":"22","author":"Weintraub W.S.","year":"2006","unstructured":"Weintraub W.S.; The vascular effects of cilostazol. Can J Cardiol 2006,22(Suppl. B),56B-60B","journal-title":"Can J Cardiol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1097\/00005344-199910000-00004","volume":"34","author":"Cone J.","year":"1999","unstructured":"Cone J.; Wang S.; Tandon N.; Fong M.; Sun B.; Sakurai K.; Yoshitake M.; Kambayashi J.; Liu Y.; Comparison of the effects of cilostazol and milrinone on intracellular cAMP levels and cellular function in platelets and cardiac cells. J Cardiovasc Pharmacol 1999,34(4),497-504","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"161","DOI":"10.2147\/CLEP.S75482","volume":"7","author":"Nietert P.J.","year":"2015","unstructured":"Nietert P.J.; Shaftman S.R.; Silver R.M.; Wolf B.J.; Egan B.M.; Hunt K.J.; Smith E.A.; Raynaud phenomenon and mortality: 20+ years of follow-up of the Charleston Heart Study cohort. Clin Epidemiol 2015,7,161-168","journal-title":"Clin Epidemiol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1016\/j.amjcard.2003.08.013","volume":"92","author":"Rajagopalan S.","year":"2003","unstructured":"Rajagopalan S.; Pfenninger D.; Somers E.; Kehrer C.; Chakrabarti A.; Mukherjee D.; Brook R.; Kaplan M.J.; Effects of cilostazol in patients with Raynaud\u2019s syndrome. Am J Cardiol 2003,92(11),1310-1315","journal-title":"Am J Cardiol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10238-015-0370-5","volume":"16","author":"Negrini S.","year":"2016","unstructured":"Negrini S.; Span\u00f2 F.; Penza E.; Rollando D.; Indiveri F.; Filaci G.; Puppo F.; Efficacy of cilostazol for the treatment of Raynaud\u2019s phenomenon in systemic sclerosis patients. Clin Exp Med 2016,16(3),407-412","journal-title":"Clin Exp Med"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.2174\/1568026619666191122123855","volume":"19","author":"Zheng H.","year":"2019","unstructured":"Zheng H.; Yang H.; Gong D.; Mai L.; Qiu X.; Chen L.; Su X.; Wei R.; Zeng Z.; Progress in the Mechanism and Clinical Application of Cilostazol. Curr Top Med Chem 2019,19(31),2919-2936","journal-title":"Curr Top Med Chem"},{"key":"ref=62","unstructured":"Pletal 50 mg tablets summary of product characteristics.\nAvailable at:  (acceesed on: 24 March, 2021)"},{"key":"ref=63","author":"Wigley F.M.","unstructured":"Wigley F.M.;  Treatment of Raynaud phenomenon: initial\nmanagement, Available at:  (acceesed on: 24 March, 2021)"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200903114154","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185529\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200903114154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:32:48Z","timestamp":1660069968000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185529\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":63,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200903114154","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-16","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}